Jonathan C. Javitt Acquires 40,000 Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt acquired 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the transaction, the chairman now directly owns 84,634 shares in the company, valued at $99,021.78. The trade was a 89.62 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

NRx Pharmaceuticals Stock Performance

NRXP stock traded down $0.12 during trading on Wednesday, hitting $1.52. 752,589 shares of the company’s stock traded hands, compared to its average volume of 203,419. The business has a fifty day simple moving average of $1.27 and a 200 day simple moving average of $1.89. NRx Pharmaceuticals, Inc. has a 52 week low of $1.10 and a 52 week high of $7.33. The stock has a market capitalization of $18.39 million, a price-to-earnings ratio of -0.83 and a beta of 1.25.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.27% of the company’s stock.

Analyst Ratings Changes

NRXP has been the subject of several analyst reports. Ascendiant Capital Markets raised their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, November 25th. Finally, EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.